Dilon’s One-Year Anniversary in Atlanta: Expanding Awareness and Portfolio in the Southeast

It’s been one year since our relocation to Atlanta in August 2017. We have been incredibly busy these past 12 months, tapping into the Southeast medtech ecosystem, building upon our national awareness, diligently and thoughtfully continuing our journey toward a dedicated reimbursement code and expanding our Radiofrequency (RF) Spectroscopy device portfolio. Here are a few of the many highlights:

Building national awareness for MarginProbe and Dune’s RF Spectroscopy Platform

In early 2018, Dune was named a 2018 Top 10 Innovative Technology Company by the Technology Association of Georgia (TAG) and took home ‘Best Overall’ honors. “These awards are given to an elite group of companies whose products and solutions are not only changing their respective industries, but also putting Georgia on the map as a state where technology innovation can thrive,” said Larry Williams, president & CEO of TAG. Our very own CEO, Lori Chmura, was named a 2018 Health Care Heroes Finalist for Health Care Innovator/Researcher by The Atlanta Business Chronicle. These awards highlight the individuals and companies that are dedicated to improving the overall health and well-being of the community.

Firmly rooted in the local ecosystem

For Tech Alpharetta, Dune CEO Lori Chmura explained the benefits of the local medtech ecosystem and her excitement to be part of it. Watch the video here.

Continuing the journey for a dedicated reimbursement code and expanding our portfolio

On the industry conferences front, we had our most productive American Society of Breast Surgeons conference ever, directly connecting with surgeons around the world and generating well over 100 leads for surgeons excited to introduce MarginProbe as a standard of care for their breast-conserving surgery patients. This includes the establishment of two new facilities in the metro Atlanta area, building our presence in our “new hometown.” The value that MarginProbe brings to reducing positive margins during oncoplastic surgery was presented by Dr. Dennis Holmes and Dr. Karen Barbosa during the Beginner and Intermediate Oncoplastic Breast Surgery Skills Courses.

We also previewed our RF platform expansion device for smart biopsies in an invitation-only innovation suite.  Our device, fully funded by the prestigious Horizon 20/20 grant, was received with great optimism for its capacity to contribute to the development of innovative breast cancer surgery advancements.  

Compelling Clinical Data continues to highlight Dune’s revolutionary RF Spectroscopy technology in the breast

The American Journal of Surgery published a study showing that MarginProbe reduces re-excision rates for breast-conserving surgery by 61%. “MarginProbe’s capacity to reduce instances of costly second surgeries while improving quality of life is exactly the kind of value-based proposition that new medical devices need to offer in today’s healthcare environment,” said Jeffrey Falk, Surgical Oncologist at St. John Hospital and Medical Centers of Ascension Michigan, one of the authors of the study.

Lori was invited to share the compelling story of Dune with hundreds of investors at the annual Jefferies Global Healthcare Conference in New York City.

Expanding the leadership team and surgeon engagement

Building upon our legacy of entrepreneurship in Israel, we have expanded the Dilon leadership team in Atlanta during the past 12 months. In October we announced Susan Turner as Vice President of Healthcare Economics and Reimbursement. Alan Bond was named Chief Financial Officer in May and Avihai Lachman was named Vice President of Research and Development in June. Along with our customer service and accounting partners, we now have 6 people in our Georgia office.

Dr. Rhonda Wachsmuth, who has practiced with Georgia Breast Care since 2013, recently discussed her experience with MarginProbe in a surgeon spotlight. “With MarginProbe, I take more margins than I would previously, yet I’m starting out with a much smaller lumpectomy, as the probe has given me the confidence to remove less tissue overall,” says Wachsmuth.

Looking ahead, we will expand our advocacy and legislative endeavors. We have joined forces with Margie Singleton of Savannah and her group of supporters, Margie’s Army, in the fight to pass Margie’s Law. This legislation would add Georgia to the list of states that require breast density as a standard reporting metric for mammograms. You can read more about Margie’s story and the implications of this legislation here.

Be sure to stay up to date with the latest Dune updates and MarginProbe news in the coming year by following us on Linkedin and Twitter! If you would like to know more about Dilon and MarginProbe, contact marketing@dunemedical.com.